共 50 条
- [1] vedolizumab trough levels at week 6 and 14 correlate with clinical remission in inflammatory bowel disease patients [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S492 - S492
- [2] Higher Infliximab Trough Levels Are Associated With Better Outcome in Paediatric Patients With Inflammatory Bowel Disease [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 (11): : 1316 - 1325
- [3] Infliximab trough levels are associated with disease activity in pediatric inflammatory bowel disease [J]. JOURNAL OF CROHNS & COLITIS, 2014, 8 : S412 - S412
- [4] Vedolizumab trough levels at Week 6 predict endoscopic and clinical remission in inflammatory bowel disease [J]. JOURNAL OF CROHNS & COLITIS, 2018, 12 : S414 - S414
- [7] Clinical Use of Infliximab Trough Levels and Antibodies to Infliximab in Pediatric Patients With Inflammatory Bowel Disease [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2017, 64 (02): : 272 - 278
- [8] Trough Levels of Infliximab at Week 6 Are Predictive of Remission at Week 14 in Pediatric Crohn's Disease [J]. JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2020, 70 (03): : 310 - 317